Skip to main content
Top
Published in: Drugs & Aging 4/2009

01-04-2009 | Original Research Article

Is Covert Medication in Norwegian Nursing Homes Still a Problem?

A Cross-Sectional Study

Authors: Dr Øyvind Kirkevold, Knut Engedal

Published in: Drugs & Aging | Issue 4/2009

Login to get access

Abstract

Background and objective: The practice of hiding medicines in nursing home patients’ food or beverages is described in only a few scientific papers. An earlier study conducted in 1999/2000 showed that covert medication was common in Norwegian nursing homes, with 11% of patients in regular nursing home units (RUs) and 17% of those in special care units for patients with dementia (SCUs) receiving at least one covert medication during the last 7 days. However, that study included few details about the medications involved. Therefore, we designed a study to obtain more detailed information about the practice of covert medication. The objectives of the study were to describe how widespread the practice is, identify the reasons for giving the medicine in disguise, determine what kinds of medicine are given in disguise, and establish who makes the decision about covert medication.
Methods: We collected data on 1943 patients (623 in SCUs and 1320 in RUs) in southeast Norway between October 2006 and February 2007. The information collected included what kind of drugs the patients received, what form the drugs were administered in and how the drugs were given. Patient characteristics such as age, sex, the patient’s level of function in terms of activities of daily living (ADL), mental capacity and behavioural and psychological symptoms were also recorded. Ward characteristics such as the type of ward, the number of beds in the ward and the number of carers working on each shift were also documented.
Descriptive statistics of the distribution of covert medication were obtained and the findings from SCUs and RUs were compared. The same approach was taken regarding information relating to who took the decision and how the practice was documented. A multilevel logistic regression analysis was performed to examine which patient and ward characteristics were associated with covert medication.
Results: Each patient was given on average 6.5 different medications on a regular basis every day. Nearly a quarter (23.5%) of patients who received medications had drugs mixed in food or beverages. Fourteen percent of the patients in SCUs and nearly 10% of the patients in RUs received medicine blended in food or beverages without their knowledge (covert medication). Compared with patients who were treated openly, a significantly higher proportion of patients who were treated covertly received antipsychotics (20% vs 30%, respectively; p < 0.001). In most cases, the decision to administer covert medication was made by the staff together with the physician or by the physician alone (61.4% of occasions in SCUs and 52.8% in RUs). About two-thirds of cases of covert medication had been documented to some extent in the patients’ records. Low mental capacity, low ADL function and the presence of agitation and learning disability were associated with covert medication. Of the ward characteristics, only staying in SCUs was associated with covert medication.
Conclusion: Our study presents evidence suggesting that the practice of covert medication may still be a problem in Norwegian nursing homes. The frequency of this practice has been only slightly reduced in the period 2000–7, but the practice is more frequently recorded in the patient’s records and the physician is today more often involved in the decision to give medicine covertly compared with 7 years ago.
Literature
1.
go back to reference Treloar A, Beats B, Philpot M. A pill in the sandwich: covert medication in food and drink. J R Soc Med 2000; 93(8): 408–11PubMed Treloar A, Beats B, Philpot M. A pill in the sandwich: covert medication in food and drink. J R Soc Med 2000; 93(8): 408–11PubMed
2.
go back to reference Axon M. Covert drugs can be right for clients. Nursing Times 2001; 97(6): 20PubMed Axon M. Covert drugs can be right for clients. Nursing Times 2001; 97(6): 20PubMed
3.
4.
go back to reference Treloar A, Philpot M, Beats B. Concealing medication in patients’ food. Lancet 2001; 357(9249): 62–4PubMedCrossRef Treloar A, Philpot M, Beats B. Concealing medication in patients’ food. Lancet 2001; 357(9249): 62–4PubMedCrossRef
5.
go back to reference Welsh S, Deahl M. Covert medication: ever ethically justifiable? Psychiatr Bull 2002; 26: 123–6CrossRef Welsh S, Deahl M. Covert medication: ever ethically justifiable? Psychiatr Bull 2002; 26: 123–6CrossRef
6.
go back to reference Carlisle D. Hidden agenda. Nurs Times 2002 May 21–27; 98(21): 24–7PubMed Carlisle D. Hidden agenda. Nurs Times 2002 May 21–27; 98(21): 24–7PubMed
7.
go back to reference Honkanen L. Point-counterpoint: is it ethical to give drugs covertly to people with dementia? No: covert medication is paternalistic. West J Med 2001; 174(4): 229PubMedCrossRef Honkanen L. Point-counterpoint: is it ethical to give drugs covertly to people with dementia? No: covert medication is paternalistic. West J Med 2001; 174(4): 229PubMedCrossRef
9.
go back to reference Covert medication: legal and practical guidance. In: Scotland Mwcf, editor. Edinburgh: Mental Welfare Commission for Scotland, 2006: 12 Covert medication: legal and practical guidance. In: Scotland Mwcf, editor. Edinburgh: Mental Welfare Commission for Scotland, 2006: 12
10.
go back to reference Kirkevold Ø, Engedal K. Concealment of drugs in food and beverages in nursing homes: cross sectional study. BMJ 2005; 330(7481): 20PubMedCrossRef Kirkevold Ø, Engedal K. Concealment of drugs in food and beverages in nursing homes: cross sectional study. BMJ 2005; 330(7481): 20PubMedCrossRef
12.
go back to reference Feiring E. Gjemmer piller i maten [editorial]. Tidsskr Nor Laegeforen 2004; 124(24): 3175 Feiring E. Gjemmer piller i maten [editorial]. Tidsskr Nor Laegeforen 2004; 124(24): 3175
14.
go back to reference Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22(9): 843–9PubMedCrossRef Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22(9): 843–9PubMedCrossRef
15.
go back to reference Macdonald AJ, Roberts A, Carpenter L. De facto imprisonment and covert medication use in general nursing homes for older people in South East England. Aging Clin Exp Res 2004; 16(4): 326–30PubMed Macdonald AJ, Roberts A, Carpenter L. De facto imprisonment and covert medication use in general nursing homes for older people in South East England. Aging Clin Exp Res 2004; 16(4): 326–30PubMed
16.
go back to reference Eek A, Nygård AM. Et hjem for deg et sted for oss: kommunenes botilbud til personer med demens. Demens 2003; 7(1): 21–3 Eek A, Nygård AM. Et hjem for deg et sted for oss: kommunenes botilbud til personer med demens. Demens 2003; 7(1): 21–3
17.
go back to reference Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3): 179–86PubMedCrossRef Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3): 179–86PubMedCrossRef
18.
go back to reference Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–72PubMedCrossRef Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–72PubMedCrossRef
19.
go back to reference Selbaek G, Kirkevold O, Sommer OH, et al. The reliability and validity of the Norwegian version of the Neuro-psychiatric Inventory, Nursing Home Version (NPI-NH). Int Psychogeriatr 2007; 20(2): 375–82PubMed Selbaek G, Kirkevold O, Sommer OH, et al. The reliability and validity of the Norwegian version of the Neuro-psychiatric Inventory, Nursing Home Version (NPI-NH). Int Psychogeriatr 2007; 20(2): 375–82PubMed
20.
go back to reference Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991 Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991
21.
go back to reference Hox J. Multilevel analysis: technics and applications. Mawah (NJ): Lawrence Erlbaum Associates, 2002 Hox J. Multilevel analysis: technics and applications. Mawah (NJ): Lawrence Erlbaum Associates, 2002
22.
go back to reference Goldstein H. Multilevel statistical models. London: Hodder Arnold, 1995 Goldstein H. Multilevel statistical models. London: Hodder Arnold, 1995
24.
go back to reference Griffith D, Bell A. An ethical dilemma [commentary]: treatment was not unethical. BMJ 1996; 313(7067): 1250CrossRef Griffith D, Bell A. An ethical dilemma [commentary]: treatment was not unethical. BMJ 1996; 313(7067): 1250CrossRef
25.
go back to reference White DMD, Hillam J, Harper M, et al. Suspension of nurse who gave drug on consultant’s instructions [commentary]. BMJ 1997; 314(7076): 299PubMedCrossRef White DMD, Hillam J, Harper M, et al. Suspension of nurse who gave drug on consultant’s instructions [commentary]. BMJ 1997; 314(7076): 299PubMedCrossRef
Metadata
Title
Is Covert Medication in Norwegian Nursing Homes Still a Problem?
A Cross-Sectional Study
Authors
Dr Øyvind Kirkevold
Knut Engedal
Publication date
01-04-2009
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2009
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200926040-00004

Other articles of this Issue 4/2009

Drugs & Aging 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.